{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:48:56Z","timestamp":1779299336926,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NCSU CMI Ideation Award"},{"name":"NCSU Comparative Medicine Institute (CMI) \/ Clinical Studies Core (CSC) New Faculty Clinical Research Award"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Local drug presentation made possible by drug-eluting depots provides benefits for a vast array of diseases, including cancer, microbial infection, and wound healing. Drug-eluting depots provide sustained drug release of therapeutics directly at disease sites with tunable kinetics, remove the need for drugs to access disease sites from circulation, and reduce the side effects associated with systemic therapy. Recently, we introduced an entirely novel approach to local drug presentation named Tissue-Reactive Anchoring Pharmaceuticals (TRAPs). TRAPs enables local drug presentation without any material carriers, capitalizing on innate tissue structures to anchor drugs at the site of administration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this report, we comprehensively evaluate the local and systemic toxicological profile of a paclitaxel version of TRAPs in mice by clinical observations, body weight monitoring, histopathological evaluations of injection sites and major organs, as well as blood and urine analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We find that intradermal administration of TRAP-paclitaxel does not induce substantial toxic effects. Localized inflammatory responses were observed at the injection sites and secondary minimal, non-specific inflammation was observed in the liver. All other organs displayed unremarkable histological findings.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These findings support the potential of TRAP-paclitaxel as a promising candidate for localized cancer treatment, offering high-concentration drug delivery while mitigating scarring and adverse side effects.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40360-024-00819-6","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T10:54:49Z","timestamp":1733396089000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Toxicology study of a tissue anchoring paclitaxel prodrug"],"prefix":"10.1186","volume":"25","author":[{"given":"Rukesh","family":"Chinthapatla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jazz Q.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel B.","family":"Neumann-Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nichol M.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minhua","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah R.","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua G.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle M.","family":"Meritet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yevgeny","family":"Brudno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"819_CR1","first-page":"14","volume":"34","author":"JL Liu","year":"2023","unstructured":"Liu JL, Zhang SX, Billette J-M, Demers AA. Lifetime probability of developing cancer and dying from cancer in Canada, 1997 to 2020. Health Rep. 2023;34:14\u201321.","journal-title":"Health Rep"},{"key":"819_CR2","doi-asserted-by":"crossref","unstructured":"Torre LA, Siegel RL, Ward EM, Jemal A. Supplementary Figs.\u00a01\u201317. From global cancer incidence and mortality rates and trends\u2014an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16\u201327","DOI":"10.1158\/1055-9965.EPI-15-0578"},{"key":"819_CR3","doi-asserted-by":"publisher","first-page":"112503","DOI":"10.1016\/j.biopha.2021.112503","volume":"146","author":"J Zeien","year":"2022","unstructured":"Zeien J, Qiu W, Triay M, Dhaibar HA, Cruz-Topete D, Cornett EM, et al. Clinical implications of chemotherapeutic agent organ toxicity on perioperative care. Biomed Pharmacother. 2022;146:112503.","journal-title":"Biomed Pharmacother"},{"key":"819_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jconrel.2011.11.031","volume":"159","author":"JB Wolinsky","year":"2012","unstructured":"Wolinsky JB, Colson YL, Grinstaff MW. Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. J Control Release. 2012;159:14\u201326.","journal-title":"J Control Release"},{"key":"819_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jconrel.2004.09.007","volume":"100","author":"T Manabe","year":"2004","unstructured":"Manabe T, Okino H, Maeyama R, Mizumoto K, Nagai E, Tanaka M, et al. Novel strategic therapeutic approaches for prevention of local recurrence of pancreatic cancer after resection: trans-tissue, sustained local drug-delivery systems. J Control Release. 2004;100:317\u201330.","journal-title":"J Control Release"},{"key":"819_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/neuonc\/5.2.79","volume":"5","author":"M Westphal","year":"2003","unstructured":"Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5:79\u201388.","journal-title":"Neuro Oncol"},{"key":"819_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.biomaterials.2016.03.044","volume":"93","author":"L Indolfi","year":"2016","unstructured":"Indolfi L, Ligorio M, Ting DT, Xega K, Tzafriri AR, Bersani F, et al. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. Biomaterials. 2016;93:71\u201382.","journal-title":"Biomaterials"},{"key":"819_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.amjcard.2006.02.042","volume":"98","author":"MJ Eisenberg","year":"2006","unstructured":"Eisenberg MJ, Konnyu KJ. Review of randomized clinical trials of drug-eluting stents for the prevention of in-stent restenosis. Am J Cardiol. 2006;98:375\u201382.","journal-title":"Am J Cardiol"},{"key":"819_CR9","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.ehj.2004.03.023","volume":"25","author":"RA Hill","year":"2004","unstructured":"Hill RA, D\u00fcndar Y, Bakhai A, Dickson R, Walley T. Drug-eluting stents: an early systematic review to inform policy. Eur Heart J. 2004;25:902\u201319.","journal-title":"Eur Heart J"},{"key":"819_CR10","doi-asserted-by":"publisher","first-page":"482","DOI":"10.2165\/00019053-199405060-00005","volume":"5","author":"MP Cramer","year":"1994","unstructured":"Cramer MP, Saks SR. Translating safety, efficacy and compliance into economic value for controlled release dosage forms. PharmacoEconomics. 1994;5:482\u2013504.","journal-title":"PharmacoEconomics"},{"key":"819_CR11","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/S0140-6736(95)90755-6","volume":"345","author":"H Brem","year":"1995","unstructured":"Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain Tumor Treatment Group. Lancet. 1995;345:1008\u201312.","journal-title":"Lancet"},{"key":"819_CR12","doi-asserted-by":"publisher","first-page":"AB257","DOI":"10.1016\/j.gie.2006.03.861","volume":"63","author":"K Matthes","year":"2006","unstructured":"Matthes K, Mino-Kenudson M, Sahani D, Holalkere NS, Fowers K, Rathi R, et al. EUS-guided injection of paclitaxel (OncoGel) provides therapeutic drug concentrations in the porcine pancreas. Gastrointest Endosc. 2006;63:AB257.","journal-title":"Gastrointest Endosc"},{"key":"819_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.surg.2005.11.012","volume":"140","author":"Y Ogura","year":"2006","unstructured":"Ogura Y, Mizumoto K, Tanaka M, Ohuchida K, Murakami M, Yamada D, et al. Strategy for prevention of local recurrence of pancreatic cancer after pancreatectomy: antitumor effect of gemcitabine mixed with fibrin glue in an orthotopic nude mouse model. Surgery. 2006;140:66\u201371.","journal-title":"Surgery"},{"key":"819_CR14","first-page":"5786","volume":"9","author":"H Okino","year":"2003","unstructured":"Okino H, Maeyama R, Manabe T, Matsuda T, Tanaka M. Trans-tissue, sustained release of gemcitabine from photocured gelatin gel inhibits the growth of heterotopic human pancreatic tumor in nude mice. Clin Cancer Res. 2003;9:5786\u201393.","journal-title":"Clin Cancer Res"},{"key":"819_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pan.2012.11.305","volume":"13","author":"V Yagublu","year":"2013","unstructured":"Yagublu V, Caliskan N, Lewis AL, Jesenofsky R, Gasimova L, L\u00f6hr J-M, et al. Treatment of experimental pancreatic cancer by doxorubicin-, mitoxantrone-, and irinotecan-drug eluting beads. Pancreatology. 2013;13:79\u201387.","journal-title":"Pancreatology"},{"key":"819_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jconrel.2016.06.015","volume":"238","author":"H-G Yi","year":"2016","unstructured":"Yi H-G, Choi Y-J, Kang KS, Hong JM, Pati RG, Park MN, et al. A 3D-printed local drug delivery patch for pancreatic cancer growth suppression. J Control Release. 2016;238:231\u201341.","journal-title":"J Control Release"},{"key":"819_CR17","doi-asserted-by":"publisher","first-page":"12381","DOI":"10.1038\/s41598-017-12670-3","volume":"7","author":"E Jun","year":"2017","unstructured":"Jun E, Kim SC, Lee CM, Oh J, Lee S, Shim IK. Synergistic effect of a drug loaded electrospun patch and systemic chemotherapy in pancreatic cancer xenograft. Sci Rep. 2017;7:12381.","journal-title":"Sci Rep"},{"key":"819_CR18","doi-asserted-by":"publisher","first-page":"40140","DOI":"10.18632\/oncotarget.17370","volume":"8","author":"IK Shim","year":"2017","unstructured":"Shim IK, Yi H-J, Yi H-G, Lee CM, Lee YN, Choi Y-J, et al. Locally-applied 5-fluorouracil-loaded slow-release patch prevents pancreatic cancer growth in an orthotopic mouse model. Oncotarget. 2017;8:40140\u201351.","journal-title":"Oncotarget"},{"key":"819_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/jbm.b.30186","volume":"73","author":"T Manabe","year":"2005","unstructured":"Manabe T, Okino H, Maeyama R, Mizumoto K, Tanaka M, Matsuda T. New infusion device for trans-tissue, sustained local delivery of anticancer agent to surgically resected tissue: potential use for suppression of local recurrence of pancreatic cancer. J Biomed Mater Res B Appl Biomater. 2005;73:203\u20137.","journal-title":"J Biomed Mater Res B Appl Biomater"},{"key":"819_CR20","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1073\/pnas.1600421113","volume":"113","author":"JD Byrne","year":"2016","unstructured":"Byrne JD, Jajja MRN, Schorzman AN, Keeler AW, Luft JC, Zamboni WC, et al. Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A. 2016;113:2200\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"819_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3892\/mco.2012.47","volume":"1","author":"K Ohara","year":"2013","unstructured":"Ohara K, Kohno M, Horibe T, Kawakami K. Local drug delivery to a human pancreatic tumor via a newly designed multiple injectable needle. Mol Clin Oncol. 2013;1:231\u20134.","journal-title":"Mol Clin Oncol"},{"key":"819_CR22","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1007\/s11095-010-0360-y","volume":"28","author":"H Holback","year":"2011","unstructured":"Holback H, Yeo Y. Intratumoral drug delivery with nanoparticulate carriers. Pharm Res. 2011;28:1819\u201330.","journal-title":"Pharm Res"},{"key":"819_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jconrel.2020.06.029","volume":"326","author":"A Huang","year":"2020","unstructured":"Huang A, Pressnall MM, Lu R, Huayamares SG, Griffin JD, Groer C, et al. Human intratumoral therapy: linking drug properties and tumor transport of drugs in clinical trials. J Control Release. 2020;326:203\u201321.","journal-title":"J Control Release"},{"key":"819_CR24","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jconrel.2022.01.023","volume":"343","author":"S Pandit","year":"2022","unstructured":"Pandit S, Palvai S, Massaro NP, Pierce JG, Brudno Y. Tissue-reactive drugs enable materials-free local depots. J Control Release. 2022;343:142\u201351.","journal-title":"J Control Release"},{"key":"819_CR25","first-page":"392","volume":"17","author":"MR Adams","year":"2020","unstructured":"Adams MR, Moody CT, Sollinger JL, Brudno Y. Extracellular-matrix-anchored click motifs for specific tissue targeting. Mol Pharm. 2020;17:392\u2013403.","journal-title":"Mol Pharm"},{"key":"819_CR26","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1517\/14656566.3.6.755","volume":"3","author":"TM Mekhail","year":"2002","unstructured":"Mekhail TM, Markman M. Paclitaxel in cancer therapy. Expert Opin Pharmacother. 2002;3:755\u201366.","journal-title":"Expert Opin Pharmacother"},{"key":"819_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-5173(98)00188-4","volume":"172","author":"R Panchagnula","year":"1998","unstructured":"Panchagnula R. Pharmaceutical aspects of paclitaxel. Int J Pharm. 1998;172:1\u201315.","journal-title":"Int J Pharm"},{"key":"819_CR28","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","volume":"332","author":"EK Rowinsky","year":"1995","unstructured":"Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995;332:1004\u201314.","journal-title":"N Engl J Med"},{"key":"819_CR29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.biomaterials.2011.09.025","volume":"33","author":"L Shan","year":"2012","unstructured":"Shan L, Cui S, Du C, Wan S, Qian Z, Achilefu S, et al. A paclitaxel-conjugated adenovirus vector for targeted drug delivery for tumor therapy. Biomaterials. 2012;33:146\u201362.","journal-title":"Biomaterials"},{"key":"819_CR30","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/10717540601098799","volume":"14","author":"T Yang","year":"2007","unstructured":"Yang T, Cui F-D, Choi M-K, Lin H, Chung S-J, Shim C-K, et al. Liposome formulation of paclitaxel with enhanced solubility and stability. Drug Deliv. 2007;14:301\u20138.","journal-title":"Drug Deliv"},{"key":"819_CR31","doi-asserted-by":"publisher","first-page":"524","DOI":"10.18433\/J3P306","volume":"13","author":"A Jouyban","year":"2010","unstructured":"Jouyban A, Fakhree MAA, Shayanfar A. Review of pharmaceutical applications of N-methyl-2-pyrrolidone. J Pharm Pharm Sci. 2010;13:524\u201335.","journal-title":"J Pharm Pharm Sci"},{"key":"819_CR32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1080\/10717540902850567","volume":"16","author":"X Li","year":"2009","unstructured":"Li X, Pan W, Ju C, Liu Z, Pan H, Zhang H, et al. Evaluation of Pharmasolve\u00ae corneal permeability enhancement and its irritation on rabbit eyes. Drug Deliv. 2009;16:224\u20139.","journal-title":"Drug Deliv"},{"key":"819_CR33","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/jps.20291","volume":"94","author":"PJ Lee","year":"2005","unstructured":"Lee PJ, Langer R, Shastri VP. Role of n-methyl pyrrolidone in the enhancement of aqueous phase transdermal transport. J Pharm Sci. 2005;94:912\u20137.","journal-title":"J Pharm Sci"},{"key":"819_CR34","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","volume":"25","author":"BA Weaver","year":"2014","unstructured":"Weaver BA. How Taxol\/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25:2677\u201381.","journal-title":"Mol Biol Cell"},{"key":"819_CR35","doi-asserted-by":"publisher","first-page":"e13395","DOI":"10.1111\/ecc.13395","volume":"30","author":"J Chan","year":"2021","unstructured":"Chan J, Adderley H, Alameddine M, Armstrong A, Arundell D, Fox R, et al. Permanent hair loss associated with taxane chemotherapy use in breast cancer: a retrospective survey at two tertiary UK cancer centres. Eur J Cancer Care (Engl). 2021;30:e13395.","journal-title":"Eur J Cancer Care (Engl)"},{"key":"819_CR36","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/jvim.12596","volume":"29","author":"C Khanna","year":"2015","unstructured":"Khanna C, Rosenberg M, Vail DM. A review of paclitaxel and novel formulations including those suitable for use in dogs. J Vet Intern Med. 2015;29:1006\u201312.","journal-title":"J Vet Intern Med"},{"key":"819_CR37","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/vco.12435","volume":"16","author":"KA Selting","year":"2018","unstructured":"Selting KA, Bechtel SM, Espinosa J, Henry CJ, Tate D, Bryan JN, et al. Evaluation of intravenous and subcutaneous administration of a novel, excipient-free, nanoparticulate formulation of paclitaxel in dogs with spontaneously occurring neoplasia. Vet Comp Oncol. 2018;16:650\u20137.","journal-title":"Vet Comp Oncol"},{"key":"819_CR38","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1634\/theoncologist.6-2-162","volume":"6","author":"PD King","year":"2001","unstructured":"King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist. 2001;6:162\u201376.","journal-title":"Oncologist"},{"key":"819_CR39","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","volume":"37","author":"H Gelderblom","year":"2001","unstructured":"Gelderblom H, Verweij J, Nooter K, Sparreboom A, Cremophor. EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590\u20138.","journal-title":"Eur J Cancer"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00819-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-024-00819-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00819-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T11:08:31Z","timestamp":1733396911000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-024-00819-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["819"],"URL":"https:\/\/doi.org\/10.1186\/s40360-024-00819-6","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"13 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal work was done in compliance with Institutional Animal Care and Use Committee (IACUC; 22-233-O; Approved 06.17.2022) policies including the National Institutes of Health\u2019s Guide for Care and Use of Laboratory Animals, National Research Council\u2019s Guide for the Care and Use of Laboratory Animals, and Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"YB is an inventor on patent applications related to Tissue-Reactive Anchoring of Pharmaceuticals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}